BHVN — Phase 3 Data for Troriluzole in OCD
Dec 31, 2025, 5:00:00 AM UTC
Summary
Biohaven anticipates results from two ongoing Phase 3 studies of Troriluzole in obsessive-compulsive disorder (OCD) in 2025, which are critical for the drug's development.
Company
BIOHAVEN LTD (BHVN)NYSE — Healthcare: Manufacturing, Biotechnology: Pharmaceutical Preparations
www.biohaven.comSimilar Events
Topline Results from Phase 2b Clinical Trial of BPL-003
Topline results from the core stage of the Phase 2b clinical trial evaluating BPL-003 in treatment-resistant depression are expected in mid-2025.
clinical readoutClinical Development Updates for LOQTORZI and Pipeline Candidates
Coherus plans to advance its novel immuno-oncology candidates, including LOQTORZI, towards key data milestones in 2026, focusing on maximizing revenues and expanding indications.
clinical readoutPhase 2b BPL-003 Study Topline Results
Topline results from the Phase 2b study of BPL-003 in treatment-resistant depression are anticipated in mid-2025.
clinical readoutCOMP005 Trial Phase 3 Data Release
Compass Pathways anticipates the release of the first Phase 3 data from the COMP005 trial in Q2 2025, which will further explore the efficacy of COMP360 psilocybin treatment for TRD.
clinical readout